CN Patent

CN101229169B — 含拉莫三嗪的缓释制剂

Assigned to Glaxo Group Ltd · Expires 2012-11-21 · 13y expired

What this patent protects

本发明涉及治疗CNS疾病的方法，其包括以缓释制剂的形式向患者经口给予治疗有效量的拉莫三嗪或其可药用衍生物。还涉及减少至少一种不良事件发生的方法，拉莫三嗪或其可药用衍生物的缓释制剂及其治疗方法和用途，以及获得血清浓度的方法。

USPTO Abstract

本发明涉及治疗CNS疾病的方法，其包括以缓释制剂的形式向患者经口给予治疗有效量的拉莫三嗪或其可药用衍生物。还涉及减少至少一种不良事件发生的方法，拉莫三嗪或其可药用衍生物的缓释制剂及其治疗方法和用途，以及获得血清浓度的方法。

Drugs covered by this patent

Patent Metadata

Patent number
CN101229169B
Jurisdiction
CN
Classification
—
Expires
2012-11-21
Drug substance claim
No
Drug product claim
No
Assignee
Glaxo Group Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.